K Phos

Potassium Phosphate, Monobasic · Tablet, Coated · Oral

Prescription (Rx)

Uses

INDICATONS AND USAGE K-PHOS® No. 2 is a highly effective urinary acidifier for use in patients with elevated urinary pH. This product helps keep calcium soluble and reduces odor and rash caused by ammoniacal urine. Also, by acidifying the urine, it increases the antibacterial activity of methenamine mandelate and methenamine hippurate.

Dosage and administration

One tablet four times daily with a full glass of water. When the urine is difficult to acidify, administer one tablet every two hours not to exceed 8 tablets in a 24-hour period.

Contraindications

This product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

Precautions

General This product contains potassium and sodium and should be used with caution if regulation of these elements is desired. Occasionally, some individuals may experience a mild laxative effect during the first few days of phosphate therapy. If laxation persists to an unpleasant degree, reduce the daily dosage until this effect subsides or, if necessary, discontinue the use of this product. Use of this medication should be carefully considered when the following medical problems exist: Cardiac disease (particularly in digitalized patients), Addison's disease, acute dehydration, extensive tissue breakdown, myotonia congenita, cardiac failure, cirrhosis of the liver or severe hepatic disease, peripheral and pulmonary edema, hypernatremia, hypertension, toxemia of pregnancy, hypoparathyroidism, and acute pancreatitis. Rickets may benefit from phosphate therapy, but caution should be observed. High serum phosphate levels increase the risk of extraskeletal calcification. Information for Patients Patients with kidney stones may pass old stones when phosphate therapy is started and should be warned of this possibility. Patients should be advised to avoid the use of antacids containing aluminum, magnesium, or calcium which may prevent the absorption of phosphate. Laboratory Tests Careful monitoring of renal function and serum calcium, phosphorus, potassium and sodium may be required at periodic intervals during phosphate therapy. Other tests may be warranted in some patients, depending on conditions. Drug Interactions The use of antacids containing magnesium, aluminum, or calcium in conjunction with phosphate preparations may bind the phosphate and prevent its absorption. Concurrent use of antihypertensives, especially diazoxide, guanethidine, hydralazine, methyldopa, or rauwolfia alkaloid; or corticosteroids, especially mineralocorticoids or corticotropin, with sodium phosphate may result in hypernatremia. Potassium-containing medications or potassium-sparing diuretics may cause hyperkalemia when used wi t h potassium phosphate. Patients should have serum potassium level determinations at periodic intervals. Plasma levels of salicylates may be increased since salicylate excretion is decreased in acidified urine. Administration of monobasic phosphates to patients stabilized on salicylates may lead to toxic salicylate levels. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term or reproduction studies in animals or humans have been performed with K-PHOS® No. 2 to evaluate its carcinogenic, mutagenic, or impairment of fertility potential. Pregnancy Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with K-PHOS® No. 2. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. This product should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

Side effects

Gastrointestinal upset (diarrhea, nausea, stomach pain and vomiting) may occur with phosphate therapy. Also, bone and joint pain (possible phosphate-induced osteomalacia) could occur. The following adverse effects may be observed (primarily from sodium or potassium): headaches; dizziness; mental confusion; seizures; weakness or heaviness of legs; unusual tiredness or weakness; muscle cramps; numbness, tingling, pain, or weakness of hands or feet; numbness or tingling around lips; fast or irregular heartbeat; shortness of breath or troubled breathing; swelling of feet or lower legs; unusual weight gain; low urine output; unusual thirst.

Drug interactions

Drug Interactions The use of antacids containing magnesium, aluminum, or calcium in conjunction with phosphate preparations may bind the phosphate and prevent its absorption. Concurrent use of antihypertensives, especially diazoxide, guanethidine, hydralazine, methyldopa, or rauwolfia alkaloid; or corticosteroids, especially mineralocorticoids or corticotropin, with sodium phosphate may result in hypernatremia. Potassium-containing medications or potassium-sparing diuretics may cause hyperkalemia when used wi t h potassium phosphate. Patients should have serum potassium level determinations at periodic intervals. Plasma levels of salicylates may be increased since salicylate excretion is decreased in acidified urine. Administration of monobasic phosphates to patients stabilized on salicylates may lead to toxic salicylate levels.

Pregnancy

Pregnancy Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with K-PHOS® No. 2. It is also not known whether this product can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. This product should be given to a pregnant woman only if clearly needed.

Description

Each tablet contains potassium acid phosphate 305 mg and sodium acid phosphate, anhydrous, 700 mg. Each tablet yields approximately 250 mg of phosphorus, 88 mg of potassium or 2.3 mEq and 134 mg of sodium or 5.8 mEq. Inactive ingredients: Lactose, magnesium stearate, microcrystalline cellulose, povidone, purified water, sodium starch glycolate, stearic acid, talc, brown coating (FD&C Blue No. 2, FD&C Red No. 40, FD&C Yellow No. 6, hypromellose, polyethylene glycol, polydextrose, titanium dioxide, triacetin).

How supplied

HOW SUPPLIED K-PHOS® No.2 is supplied as a brown, scored, capsule-shaped tablet with the name BEACH and the number 1134 imprinted on each tablet. Bottles of 100 (NDC 0486- 1134-01). STORAGE Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). [See USP] Dispense in tight, light-resistant containers with child-resistant closures.

Storage

Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). [See USP] Dispense in tight, light-resistant containers with child-resistant closures.

Patient information

Information for Patients Patients with kidney stones may pass old stones when phosphate therapy is started and should be warned of this possibility. Patients should be advised to avoid the use of antacids containing aluminum, magnesium, or calcium which may prevent the absorption of phosphate.

Label text from the FDA structured product label by Beach Products, Inc. (revised Feb 23, 2023). Long sections are shortened; the complete label is on DailyMed.

Active ingredients

Potassium Phosphate, Monobasic in 3 products
Sodium Phosphate, Dibasic, Anhydrous in 1 product
Sodium Phosphate, Monobasic, Monohydrate in 1 product
Sodium Phosphate, Monobasic, Anhydrous in 1 product

K Phos NDC products (3)

NDC	Strength & form	Labeler	Type
0486-1111	Potassium Phosphate, Monobasic 500 mg/1 Tablet, Soluble	Beach Products, Inc.	UNAPPROVED DRUG OTHER
0486-1125	Sodium Phosphate, Dibasic, Anhydrous 852 mg/1; Potassium Phosphate, Monobasic 155 mg/1; Sodium Phosphate, Monobasic,… Tablet, Coated	Beach Products, Inc.	UNAPPROVED DRUG OTHER
0486-1134	Potassium Phosphate, Monobasic 305 mg/1; Sodium Phosphate, Monobasic, Anhydrous 700 mg/1 Tablet, Coated	Beach Products, Inc.	UNAPPROVED DRUG OTHER

Frequently asked questions

What is K Phos used for?

What are the side effects of K Phos?

Who makes K Phos?

K Phos is listed by 1 labeler in the FDA NDC directory, including Beach Products, Inc..